Longitudinal assessment of the nevus phenotype in a melanoma kindred

Journal of Investigative Dermatology

Volumn 123, Issue 3, 2004, Pages 576-582

  Florell, Scott R ^a,b   Meyer, Laurence J ^a,b   Boucher, Kenneth M ^b   Porter Gill, Patricia A ^a   Hart, Marybeth ^a   Erickson, Jennica ^a   Cannon Albright, Lisa A ^b   Pershing, Lynn K ^a,b   Harris, Ronald M ^a,b   Samlowski, Wolfram E ^a,b   Zone, John J ^a,b   Leachman, Sancy A ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Familial; p16; Total nevus density; Total nevus number

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; LONGITUDINAL STUDY; MEDICAL EXAMINATION; MELANOMA; NEVUS; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL;

EID: 4143134399     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23312.x     Document Type: Article

References (35)

1. Bataille V, Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K, Cuzick J: Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: A case-control study. Br J Cancer 73:1605-1611, 1996
2. Bataille V, Grulich A, Sasieni R et al: The association between naevi and melanoma in populations with different levels of sun exposure: A joint case-control study of melanoma in the UK and Australia. Br J Cancer 77:505-510, 1998
3. Bennett DC: Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22:3063-3069, 2003
4. Bishop DT, Demenais F, Goldstein AM, et al: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894-903, 2002
5. Bishop JA, Wachsmuth RC, Harland M, et al: Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 114:28-33, 2000
6. Bliss JM, Ford D, Swerdlow AJ, et al: Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62:367-376, 1995
7. Box NF, Duffy DL, Chen W, et al: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69:765-773, 2001
8. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148-1152, 1992
9. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al: Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54:6041-6044, 1994
10. Cooke KR, Spears GF, Skegg DC: Frequency of moles in a defined population. J Epidemiol Community Health 39:48-52, 1985
11. Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH: Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J Natl Cancer Inst 83:1726-1733, 1991
12. Goldstein AM, Falk RT, Fraser MC, Dracopoli NC, Sikorski RS, Clark WH Jr, Tucker MA: Sun-related risk factors in melanoma-prone families with CDKN2A mutations. J Natl Cancer Inst 90:709-711, 1998
13. Goldstein AM, Tucker MA: Genetic epidemiology of familial melanoma. Dermatol Clin 13:605-612, 1995
14. Green A, Martin NG: Measurement and perception of skin colour in a skin cancer survey. Br J Dermatol 123:77-84, 1990
15. Green A, Siskind V, Green L: The incidence of melanocytic naevi in adolescent children in Queensland, Australia. Melanoma Res 5:155-160, 1995
16. Grulich AE, Bataille V, Swerdlow AJ, Newton-Bishop JA, Cuzick J, Mersey P, McCarthy WH: Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: A case-control study in New South Wales, Australia. Int J Cancer 67:485-491, 1996
17. Harrison SL, MacKie RM, MacLennan R: Development of melanocytic nevi in the first three years of life. J Natl Cancer Inst 92:1436-1438, 2000
18. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994
19. Kefford RF, Mann GJ: Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 15:157-161, 2003
20. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA: Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17:3245-3251, 1999
21. MacKie RM, Andrew N, Lanyon WG, Connor JM: CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111:269-272, 1998
22. MacKie RM, English J, Aitchison TC, Fitzsimons CP, Wilson P: The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 113:167-174, 1985
23. Marrett LD, King WD, Walter SD, From L: Use of host factors to identify people at high risk for cutaneous malignant melanoma. Can Med Assoc J 147:445-453, 1992
24. Meyer LJ, Goldgar DE, Cannon-Albright LA, Piepkorn MW, Zone JJ, Risman MB, Skolnick MH: Number, size, and histopathology of nevi in Utah kindreds. Cytogenet Cell Genet 59:167-169, 1992
25. Newton JA, Bataille V, Griffiths K, et al: How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 29:989-996, 1993
26. Nicholls EM: Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 32:191-195, 1973
27. Parker JF, Florell SR, Alexander A, DeSario JA, Shami PJ, Leachman SA: Pancreatic carcinoma surveillance in familial melanoma patients. Arch Dermatol 139:1019-1025, 2003
28. Piepkorn M: Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 42:705-722, 2000
29. Richard MA, Grob JJ, Gouvernet J, Culat J, Normand P, Zarour H, Bonerandi JJ: Role of sun exposure on nevus: First study in age-sex phenotype-controlled populations. Arch Dermatol 129:1280-1285, 1993
30. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JA, Clark J, Hole DJ: Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 292:1555-1559, 1986
31. Tucker MA, Boice JD Jr, Hoffman DA: Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:161-189, 1985
32. Tucker MA, Fraser MC, Goldstein AM, et al: A natural history of melanomas and dysplastic nevi: An atlas of lesions in melanoma-prone families. Cancer 94:3192-3209, 2002
33. Tucker MA, Halpern A, Holly EA, et al: Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. J Am Med Assoc 277: 1439-1444, 1997
34. Wachsmuth RC, Gaut RM, Barrett JH, et al: Heritability and gene-environment interactions for melanocytic nevus density examined in a UK adolescent twin study. J Invest Dermatol 117:348-352, 2001
35. Zhu G, Duffy DL, Eldridge A, et al: A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: A maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 65:483-492, 1999